Who are BNT162b2.B.1.351's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b5 Bivalent (Original/OMI BA.4/BA.5), Combination BNT162b2 and BNT162b2 OMI, mRNA-1273 Variant-containing Formulation, BNT162b2 (Omi KP.2), Spikevax Omicron XBB.1.5, BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bnt162b2-b-1-351.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BNT162b2.B.1.351 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BNT162b2.B.1.351 (BNT162b2.B.1.351) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

phase 3 mRNA vaccine SARS-CoV-2 spike protein (B.1.351 variant) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

BNT162b2.B.1.351 (BNT162b2.B.1.351) — BioNTech SE. BNT162b2.B.1.351 is an mRNA vaccine encoding a modified spike protein from the B.1.351 (Beta) variant of SARS-CoV-2, designed to elicit immune responses against this variant.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BNT162b2.B.1.351 TARGET	BNT162b2.B.1.351	BioNTech SE	phase 3	mRNA vaccine	SARS-CoV-2 spike protein (B.1.351 variant)
BNT162b5 Bivalent (Original/OMI BA.4/BA.5)	bnt162b5-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	Spike protein of SARS-CoV-2
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
BNT162b2 (Omi KP.2)	bnt162b2-omi-kp-2	Pfizer Inc.	marketed	mRNA vaccine	Spike protein of SARS-CoV-2
Spikevax Omicron XBB.1.5	Spikevax Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg	bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg	Pfizer	marketed	mRNA vaccine	Spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT162b2.B.1.351 — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt162b2-b-1-351. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing